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ECONOMIC AND OUTCOMES ISSUES OF 
GASTROINTESTINAL DISORDERS
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(GERD) IN A MANAGED CARE POPULATION
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O’Connor RD3, Gilderman A4
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OBJECTIVES: To document the costs, practice patterns,
patient satisfaction, and quality of life associated with
treating GERD in a managed care population. 
METHODS: This intent-to-treat study employed data
from two medical groups associated with a federally
qualified HMO in California. Patients with encounters
for IDC-9 codes: 530.00 to 530.99 (esophagus), 535.00
to 535.99 (gastritis) and 553.3 (diaphragmatic hernia)
were included. In this study 349 patients identified as be-
ginning a new GI treatment episode between 03/01/97
and 08/31/97 were sent a survey containing the MOS SF-
12 instrument and ABIM patient satisfaction survey
(score range 0–50) shortly after beginning their episode.
Patients were resurveyed 8 weeks later.
RESULTS: Surveyed patients ranged in age from 24–95
years and 58% were female. Cimetidine (59%  123/
207) was the most common H2-receptor antagonist
(H2RA) monotherapy prescribed followed by Ranitidine
(29%  60/207). Omeprazole (99%  105/106) was the
most commonly prescribed proton-pump inhibitor (PPI)
monotherapy. Treatment episode lengths, time since previ-
ous episode, and time until subsequent episode were not
significantly different for those initiating treatment on
H2RA versus PPI monotherapy. No significant changes in
baseline versus follow-up SF-12 (baseline mean PCS 
43.7, MCS  49.8) and ABIM patient satisfaction (base-
line median  44) were observed (n  103 respondents).
Total episode cost among respondents differed signifi-
cantly (p  0.02) between H2RAs (median  $84) versus
PPIs (median  $169). 
CONCLUSIONS: This study was not able to detect dif-
ferences in the patient satisfaction and quality of life in
H2RA versus PPI monotherapy in this population. As ex-
pected, episode costs were higher for PPIs versus H2RAs
(primarily due to medication costs).
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OMEPRAZOLE, AMOXICILLIN, AND 
CLARITHROMYCIN FOR H. PYLORI 
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ULCER PATIENTS
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OBJECTIVE: To determine the most cost-effective ther-
apy with the payback time for the eradication of Helico-
bacter pylori (Hp) infection in Malaysian duodenal ulcer
(DU) patients during the 1-year assumption period. 
METHODS: Decision analysis was used to compare the to-
tal cost within 1 year for Hp eradication therapies. The five
strategies compared were as follows. 1) Histamine receptor
antagonists (H2RA): acid suppression therapy for 6 weeks
followed by maintenance therapy as needed; 2) BMT 
proton pump inhibitor (PPI): bismuth (120 mg QID), met-
ronidazole (400 mg TID), tetracycline (500 mg QID), and
PPI BID for 7 days; 3) OAC: omeprazole (20 mg BID),
amoxicillin (1000 mg BID), and clarithromycin (500 mg
BID) for 7 days; 4) OMC: omeprazole (20 mg BID), met-
ronidazole (400 mg BID), and clarithromycin (500 mg BID)
for 7 days; 5) OAM: omeprazole (20 mg BID), amoxicillin
(1000 mg BID), and metronidazole (400 mg BID) for 7
days. The Hp eradication, resistance, and compliance rates
for all therapies were used in the decision analysis model.
The assumptions of medication costs, practice patterns, and
the rates used in the model were collected from literature
and from the Malaysian Expert Panel Meeting held in
Kuala Lumpur, June 1997. The total costs over 1 year for
the five treatments were analyzed and averaged by 12
months to determine when the payback period begins for
the most cost-effective triple therapy. 
RESULTS: The 1-year total costs are shown in the table
below.
H2RA maintenance therapy was the most expensive ther-
apy in the beginning and over time. The OAC regimen
was the second most expensive in terms of initial invest-
ment, but this was the most cost-effective therapy over
12 months. OAC begins to save money by month 2, com-
pared to the OMC and BMTPPI therapies. The pay-
back period for OAC, compared to all other therapies be-
gins just 4 months after investment, and from 4 months,
intervention cost savings begins, and continues through-
out the 12-month analysis period. From months 4–12 the
costs of all therapeutic regimens continue to climb—ex-
cept the OAC regimen, which stays at the lowest level, re-
sulting in cost savings. 
CONCLUSION: The payback period for the most cost-
effective regimen, OAC, begins by month 2, and pro-
duces total cost savings by month 4 compared to all other
regimens.
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Therapy H2RA BMT  PPI OMC OAM OAC
Costs (MR) 2335 1839 1786 1775 1679
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In 1994, in the UK, histamine-2-receptor antagonists
(H2RAs) were switched from prescription to non-pre-
scription, over-the-counter (OTC) status. However, the
impact of this change has not been studied. 
OBJECTIVE: The objective of this analysis was to evalu-
ate the effects of the change from prescription to OTC on
sales of gastrointestinal products (GIPs). 
METHODS: IMS provided market sales in dollars and
prescription volume for GI products from 1992 to 1997.
All sales figures were converted to 1997 US dollars using
the Consumer Price Index. 
RESULTS: Between 1992 and 1997, total spending on
GIPs increased from $1.09 billion to $1.46 billion. Con-
currently, spending on prescription GIPs rose from $940
million to $1.33 billion with a steady increase in number
of prescriptions for GIPs to 22.2 million by 1997. Since
the introduction of OTC H2RAs in 1994, their market
share amongst all H2RAs has grown modestly from 0.9%
to a high of 1.5% in 1996, when sales were approximately
$7.2 million. The market share of OTC H2RAs amongst
total OTC GIPs reached a high of 0.56% in 1995. 
CONCLUSION: The status change of H2RAs to OTC
status has had a minimal effect on the OTC GIPs sold in
the UK.
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OBJECTIVE: The purpose of this study was to develop
and refine holistic health state descriptions of diabetic pe-
ripheral neuropathy (DPN) and its complications for a
new utility instrument. 
METHODS: Quality of life domains and health state de-
scriptions related to DPN were developed through a liter-
ature review, previous focus group materials, and expert
opinion. Potential corresponding photographs were iden-
tified by expert opinion. Sixteen veterans with DPN-
related complications were recruited to participate in fo-
cus group discussions of DPN and its impact on quality
of life. Demographic and SF-36 data were also collected.
Semi-structured discussion on the health state descrip-
tions and the quality of life domains were used to refine
and face validate the health state descriptions. A psycho-
metric analysis was performed on eight additional pa-
tients to identify the most appropriate photographs to ac-
company each health state description. 
RESULTS: The mean SF-36 Physical and Mental Com-
ponent Summary scales of the participants were 28.32
and 51.69, respectively. Four broad quality of life do-
mains: symptoms of DPN (numbness, tingling, sensation,
pain, temperature detection), physical function (mobil-
ity), social function (family, leisure activities, social life)
and mental/emotional function (affect, mood, cognition)
were identified. Qualitative exploration of these domains
in four focus group discussions affirmed that these were
the domains of importance to patients. Analysis of the
empiric data from the psychometric experiment unequiv-
ocally demonstrated the photographs to accompany the
health state descriptions. 
CONCLUSIONS: Eight health state descriptions with
photographs were refined and validated by patients.
These health state descriptions will be used with U-Titer,
a customizable utility elicitation software package, to de-
rive preference weights from an at-risk population in
Canada (N  60) and the United Kingdom (N  60).
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OBJECTIVES: The uses of GI medications for the treat-
ment of and/or prophylaxis of NSAID induced gastropa-
thy can be costly and may not necessarily reduce the risk
of more serious events. The aim of this study was to ex-
amine factors influencing the length of gastrointestinal
(GI) medication usage period associated with concurrent
NSAID use. 
METHODS: This retrospective drug utilization study ex-
amined 15-month pharmacy claims records extracted
from a pharmacy benefit manager’s database. Only pa-
tients (N  454) prescribed an NSAID with no prior GI
medication use were included. This allowed the examina-
tion of those patients’ GI treatment pattern exclusively
attributable to NSAID use. GI medication treatment pe-
riod was evaluated by the Kaplan-Meier method. Factors
affecting the length of treatment period were analyzed us-
ing Cox proportional hazard regression procedure. 
RESULTS: Approximately 30% of the patients received
GI treatment longer than 180 days. The probabilities of a
patient using GI medications longer than 30, 180, and
360 days were 73.40%, 38.77%, and 22.30%, respec-
tively. The mean and median GI medication usage time is
182 and 117 days (CI  90, 147). Cox’s proportional
hazards regression indicated that advanced age (RR 
0.983; CI  0.974, 0.993), long term NSAID therapy
(RR  0.463; CI  0.348, 0.618), earlier introduction of
GI treatment (RR  1.002; CI  1.000, 1.003), and pro-
ton pump inhibitors (PPI) (RR  0.656; CI  0.469,
0.918) were associated with longer GI treatment periods. 
CONCLUSIONS: The results suggest that there is a ten-
dency for patients to receive prolonged course of GI ther-
apy once such treatment was initiated, even though they
were prescribed more potent PPIs. Further outcomes
studies should be pursued to optimize the GI medication
use associated with NSAID induced GI complications.
